
The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.

The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.

“It shows the significant poor outcomes in this population with our standard therapies and the need to improve upon that by developing novel treatments,” says Darren R. Feldman, MD.